Steven Artandi, Director of the Stanford Cancer Institute, shared a post on X:
“SCI member Beth Beadle and others report that in p16+ Oropharyngeal Cancer, quality of life outcomes at 6 months were similar for accelerated radiation with cisplatin or cetuximab, with persistent issues in dry mouth, sticky saliva, and senses.”
Title: Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial
Authors: Jolie Ringash, Pedro A. Torres-Saavedra, Maura L. Gillison, Jimmy J. Caudell, David J. Adelstein, Paul M. Harari, Erich M. Sturgis, Ethan Basch, Shlomo A. Koyfman, Greg A. Krempl, Dukagjin M. Blakaj, James Edward Bates, Thomas J. Galloway, Christopher U. Jones, Beth M. Beadle, Jonathan Harris, Quynh-Thu Le, Sue S. Yom, Benjamin Movsas
Other articles featuring Steven Artandi on OncoDaily.